Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next
Rezolute shares remain under pressure after the company’s December 11, 2025, announcement that its pivotal sunRIZE Phase 3 trial for ersodetug in congenital hyperinsulinism failed to meet primary and key secondary endpoints. The stock trades near $2.42, well below pre-trial levels, following analyst downgrades and investor-law-firm probes. Two serious hypersensitivity reactions were reported in the trial.